<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3312">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02084901</url>
  </required_header>
  <id_info>
    <org_study_id>1-2013-0083</org_study_id>
    <nct_id>NCT02084901</nct_id>
  </id_info>
  <brief_title>Comparison of Biodegradable Stents: Orsiro and BioMatrix</brief_title>
  <official_title>Comparison of Biodegradable Stents: Orsiro and BioMatrix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of a biodegradable polymer has the potential to reduce the sustained inflammatory
      response of the arterial wall, facilitating re-endothelialization and minimizing the risk of
      thrombus formation and late restenosis. In the study, we are going to two biodegradable
      polymer stents, Orsiro and BioMatrix, especially regarding the stent strut coverage by
      optical coherence tomography at 3 months after stent implantation.

      The primary objective of this study is to test the hypothesis that Orsiro is non-inferior to
      Biomatrix in terms of stent strut coverage by optical coherence tomography at 3 months. The
      secondary endpoint is clinical outcomes up to 1 year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of a biodegradable polymer has the potential to reduce the sustained inflammatory
      response of the arterial wall, facilitating re-endothelialization and minimizing the risk of
      thrombus formation and late restenosis. In the study, we are going to two biodegradable
      polymer stents, Orsiro and BioMatrix, especially regarding the stent strut coverage by
      optical coherence tomography at 3 months after stent implantation.

      The primary objective of this study is to test the hypothesis that Orsiro is non-inferior to
      Biomatrix in terms of stent strut coverage by optical coherence tomography at 3 months. The
      secondary endpoint is clinical outcomes up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Neointimal coverage at 3 month after stent implantation</measure>
    <time_frame>At 3 months after stent implantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of stent uncoverage measured by optical coherence tomography</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>All-comer</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Orsiro Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BioMatrix or BioMatrix Flex Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-eluting biodegradable stent Orsiro implantation</intervention_name>
    <description>Drug-eluting biodegradable stent Orsiro implantation</description>
    <arm_group_label>Orsiro Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation</intervention_name>
    <description>Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation</description>
    <arm_group_label>BioMatrix or BioMatrix Flex Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients â‰¥ 20 years old

          2. Patients in the treatment of subjects with all-comer who are to undergo PCI

        Exclusion Criteria:

          1. Pregnant women or women with potential childbearing

          2. Life expectancy &lt; 1 year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>March 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biodegradable stents</keyword>
  <keyword>converage</keyword>
  <keyword>OCT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
